Last reviewed · How we verify
Micronase (glibenclamide)
At a glance
| Generic name | glibenclamide |
|---|---|
| Also known as | Glibenclamida, Legrand GE, Daonil, GlibenTek, Sulfonylureas, encephaledema |
| Sponsor | Sanofi |
| Drug class | Sulfonylurea |
| Target | Sulfonylurea receptor 1, Kir6.2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1984 |
Approved indications
- Diabetes mellitus type 2
- Neonatal diabetes mellitus
Common side effects
Drug interactions
- labetalol
- levofloxacin
- metoprolol
- nadolol
- norfloxacin
- ofloxacin
- penbutolol
- pindolol
- propranolol
- rifampicin
- sotalol
- sulfamethoxazole
Key clinical trials
- Diabetes Management for Primary Healthcare Centers. (NA)
- Spinal Cord Injury Neuroprotection With Glyburide (PHASE1)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus (PHASE2)
- Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP) (PHASE2)
- OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis (PHASE1)
- Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels (PHASE3)
- Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Micronase CI brief — competitive landscape report
- Micronase updates RSS · CI watch RSS
- Sanofi portfolio CI